JP2025507154A - 眼の状態の治療を目的とした連続投薬レジメン - Google Patents

眼の状態の治療を目的とした連続投薬レジメン Download PDF

Info

Publication number
JP2025507154A
JP2025507154A JP2024553782A JP2024553782A JP2025507154A JP 2025507154 A JP2025507154 A JP 2025507154A JP 2024553782 A JP2024553782 A JP 2024553782A JP 2024553782 A JP2024553782 A JP 2024553782A JP 2025507154 A JP2025507154 A JP 2025507154A
Authority
JP
Japan
Prior art keywords
drug delivery
day
borolanib
insert
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507154A5 (enExample
Inventor
サイード サイム，
ダリオ パッジャリーノ，
オーウェン， エヌ． ダラム，
ナンシー ラーカー，
ジェイ， エス． デューカー，
ミッシェル ハワード‐スパークス，
バーゼル カルズーン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EyePoint Inc
Original Assignee
Eyepoint Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Inc filed Critical Eyepoint Pharmaceuticals Inc
Publication of JP2025507154A publication Critical patent/JP2025507154A/ja
Publication of JP2025507154A5 publication Critical patent/JP2025507154A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024553782A 2022-03-11 2023-03-10 眼の状態の治療を目的とした連続投薬レジメン Pending JP2025507154A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263318823P 2022-03-11 2022-03-11
US63/318,823 2022-03-11
US202263320984P 2022-03-17 2022-03-17
US63/320,984 2022-03-17
US202263341456P 2022-05-13 2022-05-13
US63/341,456 2022-05-13
US202263390051P 2022-07-18 2022-07-18
US63/390,051 2022-07-18
PCT/US2023/064148 WO2023173093A1 (en) 2022-03-11 2023-03-10 Continuous dosing regimen for treatment of a condition of the eye

Publications (2)

Publication Number Publication Date
JP2025507154A true JP2025507154A (ja) 2025-03-13
JP2025507154A5 JP2025507154A5 (enExample) 2026-04-07

Family

ID=85937358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553782A Pending JP2025507154A (ja) 2022-03-11 2023-03-10 眼の状態の治療を目的とした連続投薬レジメン

Country Status (9)

Country Link
US (1) US20250186398A1 (enExample)
EP (1) EP4489750A1 (enExample)
JP (1) JP2025507154A (enExample)
KR (1) KR20240156416A (enExample)
AU (1) AU2023230976A1 (enExample)
CA (1) CA3245209A1 (enExample)
IL (1) IL315333A (enExample)
TW (1) TW202400143A (enExample)
WO (1) WO2023173093A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033562A2 (en) 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
SG11201901962QA (en) 2016-09-29 2019-04-29 Equinox Sciences Llc Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
CA3066437A1 (en) * 2017-06-13 2018-12-20 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
US20210340516A1 (en) * 2020-04-29 2021-11-04 Augusta University Research Institute, Inc. Compositions containing arginase 1 for the treatment of neurovascular and retinal vascular disorders
SI4210682T1 (sl) * 2020-09-14 2026-07-31 EyePoint, Inc. Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda

Also Published As

Publication number Publication date
WO2023173093A9 (en) 2023-12-07
WO2023173093A1 (en) 2023-09-14
EP4489750A1 (en) 2025-01-15
US20250186398A1 (en) 2025-06-12
IL315333A (en) 2024-10-01
TW202400143A (zh) 2024-01-01
CA3245209A1 (en) 2023-09-14
KR20240156416A (ko) 2024-10-29
AU2023230976A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
EP4210682B1 (en) Bioerodible ocular drug delivery insert and therapeutic method
US20250186398A1 (en) Continuous dosing regimen for treatment of a condition of the eye
JP2025508127A (ja) 眼薬物送達インサートを投与することによる加齢黄斑変性症の予防方法
US20260083727A1 (en) Pharmaceutical formulations of nintedanib for intraocular use
US20250186336A1 (en) Method of treating wet age-related macular degeneration
TWI911436B (zh) 生物可侵蝕之眼用藥物遞送插入物及治療方法
HK40118701A (en) Continuous dosing regimen for treatment of a condition of the eye
HK40118703A (en) Method of treating wet age-related macular degeneration
WO2023192691A2 (en) Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease
CN118871107A (zh) 用于治疗眼睛病症的持续给药方案
CN118891040A (zh) 治疗湿性年龄相关性黄斑变性的方法
HK40118700A (en) Method of preventing age-related macular degeneration by administering an ocular drug delivery insert
CN118871106A (zh) 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法
HK40073855A (en) Bioerodible ocular drug delivery insert and therapeutic method

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260330